Specialty pharma firm Antares Pharma (ATRS) pared down its losses in the fourth quarter due to reduced R&D expenses. The company reported a loss of $3.7 million or $0.02 per share compared to $4.4 million or $0.03 per share in the prior year period. Sales declined marginally by 1% to $14 million.
On the products front, OTREXUP sales improved 17% to $4.8 million and auto injector devices sales more than doubled to $3.1 million. Development revenues decreased to $2.2 million as products under development is getting ready for market launch. With its partner AMAG Pharmaceuticals’ Makena product getting FDA approval, the company expects its top line to improve in 2018 as AMAG uses Antares’ QuickShot auto injector.
For fiscal 2017, sales improved 4% to $54.5 million, while net loss reduced to $16.7 million compared to $24.2 million, helped by reduced expenses.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company